Recoverability of Deferred Tax Assets and Other Items, and Uncertainty in Accounting Estimates
First written in FY2020. 6 of 11 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 20 of 62 companies on the "Worse" side.
- FY2026MitigatedAnnual report
「The valuation allowance decreased by ¥327,566 thousand. This decrease was primarily due to decreases in valuation allowances for tax loss carryforwards and liabilities related to retirement benefits, among other factors.」
The company states that the valuation allowance related to the recoverability of deferred tax assets decreased by ¥327.566 million. - 2026-05-13OtherRevisions to earnings forecasts
「Net income attributable to owners of the parent exceeded the previous forecast because, after carefully examining the recoverability of deferred tax assets in light of the results for the current fiscal year, future trends and future plans, we recorded deferred tax assets for the portion expected to be recovered and recorded ¥308 million as an adjustment to corporate income taxes and other taxes (a negative figure represents income).」
After examining the recoverability of deferred tax assets, the portion expected to be recovered was recorded, resulting in a ¥308 million tax benefit reflected in net income. - FY2023-Q3RestatedAnnual report
「There have been no significant changes to the assumptions described in the Notes to the securities report for the previous consolidated fiscal year, including assumptions concerning how COVID-19 will spread in the future and when it will subside.」
The company states that there have been no significant changes from the previous consolidated fiscal year in the accounting assumptions concerning the spread of the infection and the timing of its subsidence. - FY2023-Q2RestatedAnnual report
「There have been no significant changes to the assumptions described in the Notes to the securities report for the previous consolidated fiscal year, including assumptions concerning how COVID-19 will spread in the future and when it will subside.」
The company states that there have been no significant changes from the previous consolidated fiscal year in the accounting assumptions concerning the spread of COVID-19 and the timing of its subsidence. - FY2023-Q1RestatedAnnual report
「There have been no significant changes to the assumptions described in the Notes to the securities report for the previous consolidated fiscal year, including assumptions concerning how COVID-19 will spread in the future and when it will subside.」
The company states that there have been no significant changes from the previous consolidated fiscal year in the accounting assumptions concerning the spread of COVID-19 and the timing of its subsidence. - FY2022-Q2RestatedAnnual report
「There have been no significant changes to the assumptions described in the Notes to the securities report for the previous consolidated fiscal year, including assumptions concerning how COVID-19 will spread in the future and when it will subside.」
The company states that there have been no significant changes from the previous consolidated fiscal year in the accounting assumptions concerning the spread of COVID-19 and the timing of its subsidence. - FY2022-Q1RestatedAnnual report
「There have been no significant changes to the assumptions described in the Notes to the securities report for the previous consolidated fiscal year, including assumptions concerning how COVID-19 will spread in the future and when it will subside.」
The company states that there have been no significant changes from the previous consolidated fiscal year in the accounting assumptions concerning the spread of the infection and the timing of its subsidence. - FY2021MaterialisedAnnual report
「The valuation allowance increased by ¥1,159,779 thousand. This increase was primarily due to the additional recognition of valuation allowances of ¥62,750 thousand for tax loss carryforwards and ¥690,731 thousand for deductible temporary differences related to impairment losses, among other items.」
The estimation risk concerning the recoverability of deferred tax assets has been reflected in actual accounting treatment as an ¥1,159.779 million increase in valuation allowances. - FY2021-Q2Changes in accounting assumptionsAnnual report
「In preparing the consolidated financial statements for the cumulative second quarter of the fiscal year, our Group assumed, based on available information including external information, that the effects of COVID-19 would continue through the end of the current consolidated fiscal year and gradually recover from the following consolidated fiscal year onward when making accounting estimates such as impairment testing of fixed assets and assessing the recoverability of deferred tax assets, and changed some of the assumptions used through the first quarter of the fiscal year.」
The company changed its assumption to reflect that the effects of COVID-19 would continue through the end of the current consolidated fiscal year and gradually recover thereafter, and reflected this in estimates for impairment testing of fixed assets and the recoverability of deferred tax assets. - FY2021-Q1RestatedAnnual report
「There have been no significant changes to the assumptions described in the Notes to the securities report for the previous consolidated fiscal year, including assumptions concerning how COVID-19 will spread in the future and when it will subside.」
The company states that there have been no significant changes from the previous consolidated fiscal year in the accounting assumptions concerning the spread of COVID-19 and the timing of its subsidence. - FY2020First statedAnnual report
「In considering the need for valuation allowances, we assess expected future taxable income and tax planning, but changes in future performance and actual taxable income may have a material impact on the recognition of deferred tax assets.」
The company identifies the accounting estimation risk that changes in future performance and taxable income could affect the amount of deferred tax assets recognized as a new significant estimation item.